TY - JOUR T1 - Discovering prescription patterns in pediatric acute-onset neuropsychiatric syndrome patients JF - medRxiv DO - 10.1101/19004440 SP - 19004440 AU - Arturo Lopez Pineda AU - Armin Pourshafeie AU - Alexander Ioannidis AU - Collin McCloskey Leibold AU - Avis L. Chan AU - Carlos D. Bustamante AU - Jennifer Frankovich AU - Genevieve L. Wojcik Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/28/19004440.abstract N2 - Objective Pediatric acute-onset neuropsychiatric syndrome (PANS) is a complex neuropsychiatric syndrome characterized by an abrupt onset of obsessive-compulsive symptoms and/or severe eating restrictions, along with at least two concomitant debilitating cognitive, behavioral, or neurological symptoms. A wide range of pharmacological interventions along with behavioral and environmental modifications, and psychotherapies have been adopted to treat symptoms and underlying etiologies. Our goal was to develop a data-driven approach to identify treatment patterns in this cohort.Materials and Methods In this cohort study, we extracted medical prescription histories from electronic health records. We developed a modified dynamic programming approach to perform global alignment of those medication histories. Our approach is unique since it considers time gaps in prescription patterns as part of the similarity strategy.Results This study included 43 consecutive new-onset pre-pubertal patients who had at least 3 clinic visits. Our algorithm identified six clusters with distinct medication usage history which may represent clinician’s practice of treating PANS of different severities and etiologies i.e., two most severe groups requiring high dose intravenous steroids; two arthritic or inflammatory groups requiring prolonged nonsteroidal anti-inflammatory drug (NSAID); and two mild relapsing/remitting group treated with a short course of NSAID. The psychometric scores as outcomes in each cluster generally improved within the first two years.Discussion and conclusion Our algorithm shows potential to improve our knowledge of treatment patterns in the PANS cohort, while helping clinicians understand how patients respond to a combination of drugs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was partially supported via institutional funds from Stanford University. CDB is a Chan Zuckerberg Biohub investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe data that supports the findings of this study is available for research purposes upon written request, which will be reviewed on a case-by-case basis by Dr. Jennifer Frankovich, director of the Stanford PANS clinic (http://med.stanford.edu/pans), and Stanford's Institutional Review Board (IRB). http://med.stanford.edu/pans.html ER -